Interferon Beta-1B
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Interferon Beta-1b: A TxGNN Candidate for Hairy Cell Leukemia
One-Sentence Summary
Interferon Beta-1b (DrugBank DB00068) is a recombinant type I interferon; its originally approved indication and mechanism of action are not documented in this evidence pack, and the drug currently holds no marketing authorization in Finland. The TxGNN model predicts it may be effective for Hairy Cell Leukemia, with 0 registered clinical trials and 4 publications (all from 1987–1990) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no approved indication text on file (drug not marketed in Finland) |
| Predicted New Indication | Hairy Cell Leukemia |
| TxGNN Prediction Score | 99.16% |
| Evidence Level | L3 |
| Finland Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, Interferon Beta-1b belongs to the type I interferon class of biologic immunomodulators, which act via antiproliferative and immune-modulating effects on target cells.
The repurposing rationale documented for this candidate notes that type I interferons show antiproliferative and immunomodulatory activity against the malignant B cells characteristic of hairy cell leukemia, and that clinical responses to IFN alpha/beta in this disease were already being reported in the late 1980s. Importantly, this is described as historical evidence of an interferon class effect, not mechanistic validation specific to IFN beta-1b using modern methods.
Because the supporting literature predates IFN beta-1b's later, better-characterized clinical role and largely reflects small, single-arm or retrospective series, the mechanistic plausibility is reasonable but the evidence base has not been refreshed with contemporary, drug-specific studies.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 2736487 | 1989 | Prospective comparative study (vs. recombinant alpha-IFN) | Cancer | 10 HCL patients treated with recombinant beta-serine-interferon (90×10⁶ U SC TIW); 63% normalized peripheral counts, 25% showed partial hematologic improvement. |
| 2082943 | 1990 | Small clinical treatment report | American Journal of Hematology | 12 HCL patients (10 previously treated) given IV beta-ser interferon 90 MU TIW; bone marrow involvement 90–100% hairy cells at baseline. |
| 2198792 | 1990 | Small clinical treatment report (post-interferon salvage) | American Journal of Clinical Oncology | 3 HCL patients who failed alpha-2a- or beta-ser-interferon were switched to deoxycoformycin and achieved complete response (9–15+ months). |
| 3312839 | 1987 | Retrospective experience summary (UCLA) | Leukemia | 51 HCL patients across interferon trials; hematologic improvement in 96% (alpha-2b), 69% (alpha-N1), and 71% (recombinant beta-serine-interferon, early follow-up). |
Finland Market Information
Interferon Beta-1b currently holds no marketing authorization in Finland (0 license records on file).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The supporting evidence for the Hairy Cell Leukemia indication consists solely of small, single-arm, or retrospective interferon studies from 1987–1990 (Evidence Level L3), with no registered clinical trials specific to modern IFN beta-1b use in this disease. A Blocking-severity data gap (missing Finland/TFDA package-insert warnings and contraindications) prevents the required S1 safety review from being completed.
To proceed, the following is needed:
- Finland/TFDA package insert data (safety warnings, contraindications) — currently Blocking (DG001)
- Mechanism of action data specific to IFN beta-1b — currently High priority gap (DG002)
- Contemporary, drug-specific clinical validation in hairy cell leukemia (the existing literature reflects an interferon class effect from the late 1980s, not IFN beta-1b-specific modern evidence)
- Confirmation of Finland market/regulatory pathway status, given the drug currently has zero licenses on file
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.